In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme Biosurgery to buy Focal in stock swap

Executive Summary

In an all-stock transaction Genzyme Corp. is buying the 78% of surgical sealant company Focal it doesn't already own, and will merge it with Genzyme Biosurgery. The deal values Focal at $11.5mm, a discount of (pr)19% compared to market; the price is 4.4 times its sales. Genzyme will account for the transaction as a purchase.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Payment Includes Stock
    • Partial Acquisition

Related Companies